Company Analysis

C4 Therapeutics, Inc. (CCCC)

Nasdaq: CCCC · Biological Products, (No Diagnostic Substances) · Watertown, MA · filing with the SEC since 2016
Grade5.1
◀ Past 5.4● Present 5.1▶ Future 4.8
1 est.

Who runs C4 Therapeutics, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Hirsch Andrew
President & CEO. First filing Oct 2020, latest Feb 18, 2026, 1 filing in all.
Officers reporting now
7
of 15 people with a filing in the last fifteen months
Directors reporting now
8
27 people on the record since 2020
Officerssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Adams KendraChief Financial OfficerSep 2023Sep 21, 2026none
Reyno LeonardChief Medical OfficerJul 2023Jul 13, 20261 · $0.00
Hirsch AndrewPresident & CEOOct 2020Feb 18, 2026none
Boyle Scott NChief Business OfficerMar 2022Feb 18, 2026none
Mahaney PaigeChief Scientific OfficerOct 2024Feb 18, 2026none
Mossler MarkChief Accounting OfficerSep 2023Feb 18, 2026none
Schick KellyChief People OfficerMar 2022Feb 18, 2026none
Directorssales are open-market, Oct 2, 2025 to Oct 2, 2026
NameRoleFirst filingLatest filingSales, 12 months
Anderson Kenneth CarldirectorOct 2020Oct 2, 2026none
Grogan Donna RoydirectorAug 2022Oct 2, 2026none
Bessen LauradirectorAug 2022Jun 26, 2026none
Cooper Ronald Harold WilfreddirectorJun 2024Jun 26, 2026none
Fawell StephendirectorSep 2024Jun 26, 2026none
Hoerter Steven L.directorNov 2024Jun 26, 2026none
Hughes OwendirectorNov 2023Jun 26, 2026none
Koppikar UtpaldirectorMar 2022Jun 26, 2026none
Earlier names on the record12, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton CCCC · research, not advice